NASDAQ · KZIA
Kazia Therapeutics Ltd ADR
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
Loading market information…
NASDAQ · SILO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Silo Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Silo Pharma, Inc.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$4.80. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Silo Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $18.03K+0.14% vs estimate |
| Q4 2024 | Mar 28, 2025 | -$0.41-105.0% vs estimate | $18.03K+0.14% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.22-4.76% vs estimate | $18.03K+0.14% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
$1.63+$0.03 (+1.61%)
InMed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.26% below the high.
$0.37-$0.01 (-1.55%)
Soligenix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
$4.77+$0.26 (+5.76%)
CNS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.74% below the high.
$2.04-$0.06 (-2.86%)
Jaguar Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
$1.57-$0.06 (-3.38%)
GRI Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.55% below the high.
$2.34-$0.30 (-11.36%)
Titan Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.55% below the high.
$5.85-$0.21 (-3.47%)
Clearmind Medicine Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
